Title : Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Pub. Date : 2015 Sep 8

PMID : 26101915






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The rational development of IMMU-132 represents a paradigm shift as an ADC that binds a well-known moderately-cytotoxic drug, SN-38, to the anti-Trop-2 antibody. Irinotecan tumor associated calcium signal transducer 2 Homo sapiens